ReviewExpert review of anti-infective therapy2021
COVID-19: fighting the invisible enemy with microRNAs.
Review in Expert review of anti-infective therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 81 citations in OpenAlex.
- Therapeutic Applications of Poly-miRNAs and miRNA Sponges.International journal of molecular sciences · 2025Review
- Decoding the intricacies: a comprehensive analysis of microRNAs in the pathogenesis, diagnosis, prognosis and therapeutic strategies for COVID-19.Frontiers in medicine · 2024Review
- Expression patterns of lncRNA MALAT-1 in SARS-COV-2 infection and its potential effect on disease severity via miR-200c-3p and SIRT1.Biochemistry and biophysics reports · 2023Article
- COVID-19: Mechanisms, risk factors, genetics, non-coding RNAs and neurologic impairments.Non-coding RNA research · 2023Review
- The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection.Frontiers in cell and developmental biology · 2023Review
- Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology.Informatics in medicine unlocked · 2023Article
- Article
- Oral Delivery of miR-320-3p with Lipidic Aminoglycoside Derivatives at Mid-Lactation Alters miR-320-3p Endogenous Levels in the Gut and Brain of Adult Rats According to Early or Regular Weaning.International journal of molecular sciences · 2022Article
- Article
- Review
- MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.Life sciences · 2022Review
- Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy.Pharmacological research · 2022Review
- Review
- Tangled quest of post-COVID-19 infection-caused neuropathology and what 3P nano-bio-medicine can solve?The EPMA journal · 2022Review
- Distinct miRNAs associated with various clinical presentations of SARS-CoV-2 infection.iScience · 2022Article
- A Model for the Lifespan Loss Due to a Viral Disease: Example of the COVID-19 Outbreak.Infectious disease reports · 2022Article
- Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.Journal of infection and public health · 2022Review
- Article
- SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19.International journal of molecular sciences · 2022Review
- Host cell entry mediators implicated in the cellular tropism of SARS‑CoV‑2, the pathophysiology of COVID‑19 and the identification of microRNAs that can modulate the expression of these mediators (Review).International journal of molecular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe novel coronavirus (CoV) disease 2019 (COVID-19) is a viral infection that causes severe acute respiratory syndrome (SARS). It is believed that early reports of COVID-19 cases were noticed in December 2019 and soon after it became a global public health emergency. It is advised that COVID-19 transmits through human to human contact and in most cases, it remains asymptomatic. Several approaches are being utilized to control the outbreak of this fatal viral disease. microRNAs (miRNAs) are known signature therapeutic tool for the viral diseases; they are small non-coding RNAs that target the mRNAs to inhibit their post-transcriptional expression, therefore, impeding their functions, can serve as watchdogs or micromanagers in the cells. AREAS COVERED: This review work delineated COVID-19 and its association with SARS and Middle East respiratory syndrome (MERS), the possible role of miRNAs in the pathogenesis of COVID-19, and therapeutic potential of miRNAs and their effective delivery to treat COVID-19. EXPERT OPINION: This review highlighted the importance of various miRNAs and their potential role in fighting with this pandemic as therapeutic molecules utilizing nanotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.